Detection of a soluble form of CD109 in serum of CD109 transgenic and tumor xenografted mice

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Sakakura, Hiroki ^a   Murakumo, Yoshiki ^a,b   Mii, Shinji ^a   Hagiwara, Sumitaka ^a   Kato, Takuya ^a   Asai, Masato ^a   Hoshino, Akiyoshi ^a   Yamamoto, Noriyuki ^a   Sobue, Sayaka ^c   Ichihara, Masatoshi ^c   Ueda, Minoru ^a   Takahashi, Masahide ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c CHUBU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD109 ANTIGEN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURGERY; CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HALF LIFE TIME; HUMAN; HUMAN CELL; IN VIVO STUDY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD; DISEASE MODELS, ANIMAL; FEMALE; HEK293 CELLS; HETEROGRAFTS; HUMANS; MICE; MICE, TRANSGENIC; NEOPLASM PROTEINS; NEOPLASMS; TUMOR BURDEN;

EID: 84896487457     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083385     Document Type: Article

References (28)

1. Sutherland DR, Yeo E, Ryan A, Mills GB, Bailey D, et al. (1991) Identification of a cell-surface antigen associated with activated T lymphoblasts and activated platelets. Blood 77: 84-93.
2. Haregewoin A, Solomon K, Hom RC, Soman G, Bergelson JM, et al. (1994) Cellular expression of a GPI-linked T cell activation protein. Cell Immunol 156: 357-370. (Pubitemid 24252890)
3. a/b alloantigens to the glycosylphosphatidylinositol-anchored protein CD109 on human platelets. Blood 86: 2807-2814.
4. Lin M, Sutherland DR, Horsfall W, Totty N, Yeo E, et al. (2002) Cell surface antigen CD109 is a novel member of the a2 macroglobulin/C3, C4, C5 family of thioester-containing proteins. Blood 99: 1683-1691. doi: 10.1182/blood.V99.5.1683. (Pubitemid 34533042)
5. a/b alloantigen system on human platelets. Blood 75: 2172-2176.
6. + cells enriched in hematopoietic stem and progenitor cells. Exp Hematol 27: 1282-1294. doi: 10.1016/S0301- 472X(99)00071-5.
7. - hematopoietic and mesenchymal stem cell subsets. Ann NY Acad Sci 996: 227-230. doi: 10.1111/j.1749-6632.2003.tb03250.x.
8. Hashimoto M, Ichihara M, Watanabe T, Kawai K, Koshikawa K, et al. (2004) Expression of CD109 in human cancer. Oncogene 23: 3716-3720. doi:10.1038/sj.onc.1207418. (Pubitemid 38658439)
9. Zhang JM, Hashimoto M, Kawai K, Murakumo Y, Sato T, et al. (2005) CD109 expression in squamous cell carcinoma of the uterine cervix. Pathol Int 55: 165-169. doi: 10.1111/j.1440-1827.2005.01807.x. (Pubitemid 40676925)
10. Sato T, Murakumo Y, Hagiwara S, Jijiwa M, Suzuki C, et al. (2007) High-level expression of CD109 is frequently detected in lung squamous cell carcinomas. Pathol Int 57: 719-724. doi: 10.1111/j.1440-1827.2007.02168.x. (Pubitemid 47537632)
11. Hasegawa M, Hagiwara S, Sato T, Jijiwa M, Murakumo Y, et al. (2007) CD109, a new marker for myoepithelial cells of mammary, salivary, and lacrimal glands and prostate basal cells. Pathol Int 57: 245-250. doi: 10.1111/j.1440-1827.2007.02097.x. (Pubitemid 46595030)
12. Hasegawa M, Moritani S, Murakumo Y, Sato T, Hagiwara S, et al. (2008) CD109 expression in basal-like breast carcinoma. Pathol Int 58: 288-294. doi: 10.1111/j.1440-1827.2008.02225.x. (Pubitemid 351579639)
13. Mii S, Murakumo Y, Asai N, Jijiwa M, Hagiwara S, et al. (2012) Epidermal hyperplasia and appendage abnormalities in mice lacking CD109. Am J Pathol 181: 1180-1189. doi: 10.1016/j.ajpath.2012.06.021.
14. Hagiwara S, Murakumo Y, Sato T, Shigetomi T, Mitsudo K, et al. (2008) Upregulation of CD109 expression is associated with carcinogenesis of the squamous epithelium of the oral cavity. Cancer Sci 99: 1916-1923. doi: 10.1111/j.1349-7006.2008.00949.x.
15. Ohshima Y, Yajima I, Kumasaka MY, Yanagishita T, Watanabe D, et al. (2010) CD109 expression levels in malignant melanoma. J Dermatol Sci 57: 140-142. doi: 10.1016/j.jdermsci.2009.11.004.
16. Hagikura M, Murakumo Y, Hasegawa M, Jijiwa M, Hagiwara S, et al. (2010) Correlation of pathological grade and tumor stage of urothelial carcinomas with CD109 expression. Pathol Int 60: 735-743. doi: 10.1111/j.1440-1827.2010.02592.x.
17. Finnson KW, Tam BY, Liu K, Marcoux A, Lepage P, et al. (2006) Identification of CD109 as part of the TGF-β receptor system in human keratinocytes. FASEB J 20: 1525-1527. doi: 10.1096/fj.05-5229fje.
18. Hagiwara S, Murakumo Y, Mii S, Shigenomi T, Yamamoto N, et al. (2010) Processing of CD109 by furin and its role in the regulation of TGF-β signaling. Oncogene 29: 2181-2191. doi:10.1038/onc.2009.506.
19. Litvinov IV, Bizet AA, Binamer Y, Jones DA, Sasseville D, et al. (2011) CD109 release from the cell surface in human keratinocytes regulates TGF-β receptor expression, TGF-β signalling and STAT3 activation: relevance to psoriasis. Exp Dermatol 20: 627-632. doi: 10.1111/j.1600-0625.2011.01288.x.
20. Caccia D, Zanetti Domingues L, Miccichè F, De Bortoli M, Carniti C, et al. (2011) Secretome compartment is a valuable source of biomarkers for cancer-relevant pathways. J Proteome Res 9: 4196-4207. doi: 10.1021/pr200344n.
21. Niwa H, Yamamura K, Miyazaki J (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108: 193-199.
22. Ichihara M, Hara T, Kim H, Murate T, Miyajima A (1997) Oncostatin M and leukemia inhibitory factor do not use the same functional receptor in mice. Blood 90: 165-173. (Pubitemid 27276559)
23. Yoshimasu T, Maebeya S, Suzuma T, Bessho T, Tanino H, et al. (1999) Disappearance curves for tumor markers after resection of intrathoracic malignancies. Int J Biol Markers 14: 99-105. (Pubitemid 29312993)
24. Imber MJ, Pizzo SV (1981) Clearance and binding of two electrophoretic "fast" forms of human α2-macroglobulin. J Biol Chem 256: 8134-8139. (Pubitemid 12229851)
25. Janik JE, Morris JC, Pittaluga S, McDonald K, Raffeld M, et al. (2004) Elevated serum soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma. Blood 104: 3355-3357. (Pubitemid 39507157)
26. Ebos JM, Lee CR, Bogdanovic E, Alami J, Van Slyke P, et al. (2008) Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res 68: 521-529. doi: 10.1158/0008-5472.CAN-07-3217. (Pubitemid 351380080)
27. Kim SC, Park HM, Lee SN, Han WS (2004) Expression of epidermal growth factor receptor in cervical tissue and serum in patients with cervical neoplasia. J Low Genit Tract Dis 8: 292-297. (Pubitemid 39332204)
28. Vaidyanathan K, Vasudevan DM (2012) Organ specific tumor markers: what's new? Ind J Clin Biochem 27: 110-20.